ABSTRACT
Hepatocellular carcinoma (HCC) is among the most common and lethal human cancers worldwide. Despite curative resection, high recurrence of HCC remains a big threat, leading to poor patient outcomes. Hepatitis B virus (HBV) pre-S mutants, which harbor deletions over pre-S1 and pre-S2 gene segments of large surface proteins, have been implicated in HCC recurrence. Therefore, a reliable approach for detection of pre-S mutants is urgently needed for predicting HCC recurrence to improve patient survival. In this study, we used a next-generation sequencing (NGS)-based platform for quantitative detection of pre-S mutants in the plasma of HBV-related HCC patients and evaluated their prognostic values in HCC recurrence. We demonstrated that the presence of deletions spanning the pre-S2 gene segment and the high percentage of pre-S2 plus pre-S1 + pre-S2 deletions, either alone or in combination, was significantly and independently associated with poor recurrence-free survival and had greater prognostic performance than other clinicopathological and viral factors in predicting HCC recurrence. Our data suggest that the NGS-based quantitative detection of pre-S mutants in plasma represents a promising approach for identifying patients at high risk for HBV-related HCC recurrence after surgical resection in a noninvasive manner.
Subject(s)
Capsid Proteins/genetics , Carcinoma, Hepatocellular/virology , Hepatitis B virus/genetics , Liver Neoplasms/virology , Neoplasm Recurrence, Local/virology , Adult , Aged , Capsid Proteins/blood , Carcinoma, Hepatocellular/blood , Female , Gene Deletion , Genotype , Hepatitis B, Chronic/blood , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/virology , High-Throughput Nucleotide Sequencing , Humans , Liver Neoplasms/blood , Male , Middle Aged , Mutation , Neoplasm Recurrence, Local/blood , Prognosis , Retrospective StudiesABSTRACT
INTRODUCTION: The purpose of this study is to evaluate the diagnostic value of macrophage migration inhibitory factor in patients with nasopharyngeal carcinoma. MATERIALS AND METHODS: The expression levels of macrophage migration inhibitory factor in nasopharyngeal carcinoma cell lines, tumor tissues, and plasma were measured by real-time polymerase chain reaction, Western blotting, enzyme-linked immunosorbent assay, and immunohistochemistry. Plasma Epstein-Barr virus viral capsid antigen was determined by immunoenzymatic techniques. RESULTS: Both the messenger RNA and protein expression levels of macrophage migration inhibitory factor were upregulated in nasopharyngeal carcinoma cell lines and nasopharyngeal carcinoma tissues. Macrophage migration inhibitory factor in plasma was significantly elevated in patients with nasopharyngeal carcinoma compared to Epstein-Barr virus viral capsid antigen-negative and Epstein-Barr virus viral capsid antigen-positive healthy donors. The combination of macrophage migration inhibitory factor and Epstein-Barr virus viral capsid antigen was better for diagnosing nasopharyngeal carcinoma (area under receiver operating characteristic curve = 0.925, 95% CI: 0.898-0.951) than macrophage migration inhibitory factor (area under receiver operating characteristic curve = 0.778, 95% CI: 0.732-0.824) and Epstein-Barr virus viral capsid antigen. Combining macrophage migration inhibitory factor and Epstein-Barr virus viral capsid antigen had higher specificity (82.40% vs 69.96%) and higher positive predictive value (79.17% vs 67.44%) without an obvious reduction in sensitivity (95.25%) compared to Epstein-Barr virus viral capsid antigen alone. Macrophage migration inhibitory factor was highly expressed in nasopharyngeal carcinoma cell lines, whereas it was not associated with Epstein-Barr virus infection. The level of macrophage migration inhibitory factor in plasma was not related to the titer of Epstein-Barr virus viral capsid antigen. CONCLUSION: The combination of macrophage migration inhibitory factor and Epstein-Barr virus viral capsid antigen increases the specificity and positive predictive value of detecting nasopharyngeal carcinoma and improves the diagnostic accuracy of nasopharyngeal carcinoma in high-risk individuals.
Subject(s)
Antigens, Viral/blood , Biomarkers, Tumor/blood , Capsid Proteins/blood , Epstein-Barr Virus Infections/complications , Herpesvirus 4, Human/isolation & purification , Immunoglobulin G/blood , Intramolecular Oxidoreductases/blood , Macrophage Migration-Inhibitory Factors/blood , Nasopharyngeal Neoplasms/diagnosis , Adolescent , Adult , Aged , Case-Control Studies , China/epidemiology , Epstein-Barr Virus Infections/virology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Nasopharyngeal Neoplasms/blood , Nasopharyngeal Neoplasms/epidemiology , Nasopharyngeal Neoplasms/virology , Prognosis , Young AdultABSTRACT
Dermatomyositis is an inflammatory disorder involving muscle and skin. Similar to many other autoimmune diseases, environmental factors appear to trigger the onset of disease in some cases. Many drugs have been reported to be associated with dermatomyositis, and rarely infections have been described as potential triggering agents. Here we are describing a case of dermatomyositis that developed after doxycycline and levofloxacin use, who also had recent Epstein-Barr virus infection. Dermatomyositis associated with doxycycline or levofloxacin use has not yet been described in the literature, while reports of dermatomyositis after Epstein-Barr virus infection have been rare and limited to juvenile dermatomyositis or in association with cancer. It is important for clinicians to be aware of this rare association so that the diagnosis and treatment can be exercised promptly.
Subject(s)
Anti-Bacterial Agents/adverse effects , Dermatomyositis/chemically induced , Dermatomyositis/virology , Doxycycline/adverse effects , Epstein-Barr Virus Infections/complications , Levofloxacin/adverse effects , Antigens, Viral/blood , Capsid Proteins/blood , Dermatomyositis/blood , Dermatomyositis/drug therapy , Epstein-Barr Virus Infections/blood , Epstein-Barr Virus Nuclear Antigens/blood , Humans , Treatment OutcomeABSTRACT
Several studies have substantiated the correlation between reactive oxygen species (ROS) and Sirtuin 1 (SIRT1). Normally, enterovirus 71 (EV71) is associated with severe clinical manifestations and death. However, the effect of EV71 on the induction of cellular death and the interplay between ROS/SIRT1 in cell death has not been confirmed yet. In the current study, an increase in the number of apoptotic cells was observed as soon as the EV71 infection was initiated in cells and mice. Furthermore, EV71 infection also promoted a rise in the levels of three commonly known proinflammatory cytokines, interleukin 1ß (IL-1ß), IL-6, and tumor necrosis factor-α. During EV71-induced apoptosis in the different cell lines, ROS generation and SIRT1 downregulation were observed. Further investigations showed that the administration of ROS inhibitor, N-acetyl- l-cysteine (NAC), reduced the level of apoptosis and inflammation, reduced EV71 propagation, and increased SIRT1 expression in EV71-infected cells. In addition, combined administration of NAC and EX527 (SIRT1 inhibitor) restored apoptosis in the EV71-infected cells, which was reduced due to NAC. This data demonstrated that ROS generation is positively associated with EV71-induced apoptosis and inflammation, while this effect could be reversed by SIRT1 inhibition. Collectively, we have shown that EV71 induces apoptosis and inflammation by promoting ROS generation and reducing SIRT1 expression.
Subject(s)
Apoptosis , Enterovirus A, Human/metabolism , Enterovirus Infections/metabolism , Reactive Oxygen Species/metabolism , Signal Transduction , Sirtuin 1/metabolism , Animals , Capsid Proteins/blood , Chlorocebus aethiops , Cytokines/metabolism , Disease Models, Animal , Enterovirus Infections/virology , Female , HT29 Cells , HeLa Cells , Humans , Mice, Inbred ICR , RNA, Messenger/blood , THP-1 Cells , Vero CellsABSTRACT
We developed a rapid fluorescent microsphere immunochromatographic test strip (FM-ICTS) assay for the quantitative detection of avian leukosis virus (ALV). A monoclonal antibody specific for the ALV major capsid protein encoded by the gag gene was coupled to label fluorescent microspheres. ALV antibodies were coated on a nitrocellulose membrane to prepare a test line for sample detection. The fluorescence signals of the test and control lines can be read either visually by exposure to UV light or using a fluorescence analyzer. ALV could be detected quantitatively using the ratio of fluorescence signals of the test and control lines (T/C). The assay threshold was determined as a T/C value of 0.0606. The fitting curve equation was established between 1 and 2,048 ng/mL P27 protein with an r2 value of 0.9998. The assay showed no cross reactivity with Newcastle disease virus, infectious laryngotracheitis virus, infectious bronchitis virus, Marek's disease virus, infectious bursal disease, Reoviridae virus, or avian influenza virus. The repeatability was satisfactory with an overall average CV of 8.65%. The Kappa coefficient between a commercial ELISA kit was 0.7031 using clinical chicken meconium samples. Thus, a simple, rapid, sensitive, and specific fluorescent microsphere immunochromatographic test strip was developed based on specific anti-capsid protein p27 monoclonal antibodies.
Subject(s)
Avian Leukosis Virus/isolation & purification , Avian Leukosis/diagnosis , Chickens , Immunoassay/veterinary , Poultry Diseases/diagnosis , Animals , Antibodies, Monoclonal/blood , Antibodies, Viral/blood , Capsid Proteins/blood , Immunoassay/instrumentation , Immunoassay/methods , MicrospheresABSTRACT
Background & objectives: West Nile virus (WNV) is a neurotropic flavivirus that has emerged globally as a significant cause of viral encephalitis. The early confirmatory diagnosis of WNV infections is important for timely clinical management and in areas where multiple flaviviruses are endemic. Diagnosis of WNV infection is primarily based on serodiagnosis, followed by virus isolation and identification. The aim of this study was to develop and evaluate a highly sensitive and specific immunoglobulin M (IgM) ELISA using the recombinant CprM protein (rWNV-CprM) for rapid, early and accurate diagnosis of WNV. Methods: The gene coding for the CprM protein of WNV was cloned and expressed in pET 28a vector followed by purification. An indirect IgM microplate ELISA using purified rWNV-CprM protein was optimized having no cross-reactivity with healthy human serum and serum samples obtained from patients with dengue and Japanese encephalitis viruses infection. Results: The comparative evaluation of this rWNV-CprM protein-specific IgM ELISA with plaque reduction neutralization test using 105 blood samples collected from patients suspected to have acute WNV infection revealed 98 per cent concordance with sensitivity and specificity of 100 and 97 per cent, respectively. Interpretation & conclusions: The recombinant CprM protein-based WNV-specific ELISA reported in this study may be useful for rapid screening of large numbers of blood samples in endemic areas during outbreaks.
Subject(s)
Recombinant Proteins/isolation & purification , Viral Envelope Proteins/blood , West Nile Fever/blood , West Nile virus/isolation & purification , Antibody Formation/immunology , Capsid Proteins/blood , Capsid Proteins/isolation & purification , Cloning, Molecular , Enzyme-Linked Immunosorbent Assay , Humans , Recombinant Proteins/blood , Recombinant Proteins/immunology , Serologic Tests , Viral Envelope Proteins/isolation & purification , West Nile Fever/immunology , West Nile Fever/virology , West Nile virus/immunology , West Nile virus/pathogenicitySubject(s)
Anti-Bacterial Agents/therapeutic use , Ceftriaxone/therapeutic use , Pneumocystis carinii/isolation & purification , Pneumonia, Bacterial/drug therapy , Prednisolone/therapeutic use , Shock, Hemorrhagic/mortality , Anti-Inflammatory Agents , Antigens, Viral/blood , Capsid Proteins/blood , Chills/etiology , Diagnosis, Differential , Dyspnea/etiology , Fatal Outcome , Fever/etiology , Humans , Male , Middle AgedABSTRACT
Hand, foot, and mouth disease (HFMD) is well recognized as one of the major threats to children's health globally. The increasing complexity of the etiology of HFMD still challenges disease control in China. There is little surveillance of the molecular epidemiological characteristics of the enteroviruses (EVs) that cause HFMD in Neijiang city or the Sichuan Basin area in Southwest China. In this study, demographic and epidemiological information for 14,928 probable HFMD cases was extracted and analyzed to describe the epidemic features of HFMD in Neijiang city from Jan 2010 to Dec 2017. The swab samples of select probable HFMD cases from 2012 to 2017 were tested by reverse transcription (RT) real-time PCR to identify the serotype distribution of EVs, and 110 randomly selected RT-real-time PCR positive samples were then amplified and analyzed for the VP1 or VP4 regions of EVs to further analyze the phylogenetic characteristics of the circulating strains in this area. The eight-year average annual incidence was 49.82 per 100,000 in Neijiang. The incidence rates varied between 19.51 and 70.73 per 100,000, demonstrating peaks of incidence in even-number years (2012, 2014 and 2016). The median age of the probable cases was 27 months and the interquartile range (25th to 75th percentile) of ages for the probable HFMD cases was between 14 and 42 months. The male-to-female ratio of the probable HFMD cases was 1.47:1, and scattered children were the major population classification (81.7%). Two epidemic peaks were observed: one major peak between April and July and the other lesser peak between October and December. Of 6513 probable cases tested with RT-real-time PCR, 4015 (61.6%) were positive for enterovirus with the serotype distribution as follows: EV71+, 30.1% (n = 1210); CV-A16+, 28.7% (n = 1154) and a sole pan-enterovirus+, 41.1% (n = 1651). A total of 91 cases (82.7%, 91/110) were successfully amplified and underwent phylogenetic analysis: all EV71+ cases were C4a serotype (n = 23/30); all CV-A16+ cases were B2b serotype (n = 24/30); of 42 sole pan-enterovirus+ samples, 20 were CV-A6, 14 were CV-A10 and the rest within this group were CV-A4 (n = 4), CV-A8 (n = 2), CV-A9 (n = 1) and CV-B3 (n = 1). Our findings provide important evidence that aids the improvement of strategies for vaccination against HFMD and comprehensive disease control in China.
Subject(s)
Capsid Proteins , Enterovirus B, Human/genetics , Hand, Foot and Mouth Disease , Phylogeny , Serogroup , Viral Structural Proteins , Capsid Proteins/blood , Capsid Proteins/genetics , Child, Preschool , China/epidemiology , Female , Hand, Foot and Mouth Disease/blood , Hand, Foot and Mouth Disease/epidemiology , Hand, Foot and Mouth Disease/genetics , Hand, Foot and Mouth Disease/virology , Humans , Incidence , Infant , Male , Retrospective Studies , Reverse Transcriptase Polymerase Chain Reaction , Seroepidemiologic Studies , Viral Structural Proteins/blood , Viral Structural Proteins/geneticsABSTRACT
Type 1 diabetes is a multi-factorial disease that can develop due to the combination of genetic and environmental factors. Viruses, particularly enteroviruses, are major environmental candidates in the pathogenesis of type 1 diabetes, even though the mechanisms of pathogenicity of these viruses and their effects on the immune system have not been understood very well yet. Previous studies show that any imbalance in the population of different lymphocyte subsets could develop autoimmune diseases. Our theory is that enteroviral infection causes an impairment in the distribution of lymphocyte subtypes and consequently results in the diabetes onset in some individuals. Therefore, in this project, we evaluated the distribution of T CD8+ lymphocytes and their subsets in type 1 diabetes patients. This study was conducted to investigate the relationship between enteroviral infection and type 1 diabetes mellitus in an Iranian population, and suggestion a predicting approach for susceptible subjects.
Subject(s)
Antibodies, Viral/blood , CD8-Positive T-Lymphocytes/immunology , Diabetes Mellitus, Type 1/immunology , Enterovirus Infections/immunology , Enterovirus/immunology , T-Lymphocyte Subsets/immunology , Adolescent , Adult , Antigens, CD/blood , Antigens, CD/genetics , Antigens, CD/immunology , CD8-Positive T-Lymphocytes/pathology , Capsid Proteins/blood , Capsid Proteins/genetics , Capsid Proteins/immunology , Case-Control Studies , Child , Child, Preschool , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/virology , Enterovirus/pathogenicity , Enterovirus Infections/complications , Enterovirus Infections/genetics , Enterovirus Infections/virology , Female , Gene Expression , Glutamate Decarboxylase/blood , Glutamate Decarboxylase/genetics , Glutamate Decarboxylase/immunology , Humans , Immunophenotyping , Iran , Lymphocyte Count , Male , T-Lymphocyte Subsets/pathologyABSTRACT
TGF-ß1rs1982073 polymorphism at the miRNA-187 binding site may alter TGF-ß1 expression and function, and thereby this polymorphism (genotype CT/CC) increases cancer susceptibility. HPV16 L1 seropositivity is associated with the risk of oral squamous cell carcinoma (OSCC), including oropharyngeal squamous cell carcinoma (OPSCC) and oral cavity squamous cell carcinoma (OCSCC). Thus, we hypothesized that TGF-ß1rs1982073 polymorphism at the miRNA-187 binding site combined with HPV16 L1 seropositivity may have a joint effect on OSCC susceptibility. We determined the genotypes of TGF-ß1rs1982073 and HPV16 status in 325 OSCC subjects and 335 cancer-free controls in the non-Hispanic white population, and used logistic regression models to evaluate the joint effects on OSCC susceptibility. TGF-ß1rs1982073 polymorphism (CT/CC genotype) combined with HPV16 L1 seropositivity increased the risk of OSCC via joint effects, particularly in OPSCC subjects who were never-smokers (OR, 165.9; 95% CI, 28.6-960.4) or never-drinkers (OR, 196.0; 95% CI, 28.2-1,000.0), respectively. Younger subjects had a higher risk of OPSCC than older subjects (OR, 23.5; 95% CI, 6.3-87.0 vs. OR, 6.0; 95% CI, 1.7-17.9, respectively). The significant associations between this polymorphism and HPV16-associated OSCC and OPSCC were also observed. However, OCSCC subjects did not have similar results. Our findings suggest that the joint effects of TGF-ß1rs1982073 and HPV16 L1 seropositivity can increase risk of HPV16-associated oral cancer, particularly in OPSCC subjects who are never-smokers, never-drinkers and young. This result may help us understand the tumorigenesis process and improve early detection, which are critical for prevention and intervention strategies. However, larger studies are needed to validate our findings.
Subject(s)
Capsid Proteins/blood , Carcinoma, Squamous Cell/virology , MicroRNAs/genetics , Oncogene Proteins, Viral/blood , Oropharyngeal Neoplasms/virology , Papillomavirus Infections/complications , Polymorphism, Single Nucleotide , Transforming Growth Factor beta1/genetics , Binding Sites , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Case-Control Studies , Female , Follow-Up Studies , Genetic Predisposition to Disease , Genotype , Human papillomavirus 16/isolation & purification , Humans , Male , MicroRNAs/metabolism , Middle Aged , Oropharyngeal Neoplasms/genetics , Oropharyngeal Neoplasms/metabolism , Papillomavirus Infections/blood , Papillomavirus Infections/virology , Prognosis , Transforming Growth Factor beta1/metabolismABSTRACT
BACKGROUND: The Epstein-Barr virus (EBV) is one of the most common viruses found in humans, causing lifelong infection in up to 95% of the world population. OBJECTIVES: To analyze the seroprevalence of EBV infection in different population groups in Croatia. METHODS: During a 2 year period (2015-2016), a total of 2022 consecutive serum samples collected from Croatian residents were tested for the presence of EBV-specific viral capsid antigen (VCA) immunoglobulin M (IgM) and IgG antibodies using an enzyme-linked immunoassay. IgM/IgG-positive samples were further tested for IgG avidity. RESULTS: The overall prevalence of EBV IgG antibodies was 91.4%. Females had significantly higher IgG seroprevalence than males (93.1% vs. 89.9%, P = 0.008). According to age, IgG seropositivity increased progressively from 59.6% in children age < 9 years to 98.3% in 30-39 year olds, and remained stable thereafter (P < 0.001). The IgG seroprevalence differed significantly among groups: 68.1% in children/adolescents and 95.9% in adults; multiple sclerosis (100%), hemodialysis patients (97.7%), heart transplant recipients (93.8%), hematological malignancies (91.2%), and Crohn's disease (88.5%), P < 0.001. IgM antibodies were detected in 9% of participants. Using IgG avidity, recent primary EBV infection was documented in 83.8% of IgM-positive subjects < 9 years old, 69.2% age 10-19, 33.3% age 20-29, and 3.6-4.2% > 40. All IgM positive participants > 40 years showed high IgG avidity. Logistic regression showed that age is associated with EBV IgG seropositivity. CONCLUSIONS: EBV is widespread in the Croatian population. Older age appears to be the main risk factor for EBV seropositivity.
Subject(s)
Antigens, Viral/blood , Capsid Proteins/blood , Epstein-Barr Virus Infections/epidemiology , Herpesvirus 4, Human/isolation & purification , Immunoglobulin G/blood , Immunoglobulin M/blood , Adolescent , Adult , Age Factors , Antibodies, Viral/blood , Child , Croatia/epidemiology , Enzyme-Linked Immunosorbent Assay , Epstein-Barr Virus Infections/blood , Female , Humans , Logistic Models , Male , Middle Aged , Risk Factors , Seroepidemiologic Studies , Young AdultABSTRACT
The family of polyomaviruses, which cause severe disease in immunocompromised hosts, has expanded substantially in recent years. To accommodate measurement of IgG seroresponses against all currently known human polyomaviruses (HPyVs), including the Lyon IARC polyomavirus (LIPyV), we extended our custom multiplex bead-based HPyV immunoassay and evaluated the performance of this pan-HPyV immunoassay. The VP1 proteins of 15 HPyVs belonging to 13 Polyomavirus species were expressed as recombinant glutathione S-transferase (GST) fusion proteins and coupled to fluorescent Luminex beads. Sera from healthy blood donors and immunocompromised kidney transplant recipients were used to analyze seroreactivity against the different HPyVs. For BK polyomavirus (BKPyV), the GST-VP1 fusion protein-directed seroresponses were compared to those obtained against BKPyV VP1 virus-like particles (VLP). Seroreactivity against most HPyVs was common and generally high in both test populations. Low seroreactivity against HPyV9, HPyV12, New Jersey PyV, and LIPyV was observed. The assay was reproducible (Pearson's r2 > 0.84, P < 0.001) and specific. Weak but consistent cross-reactivity between the related viruses HPyV6 and HPyV7 was observed. The seroresponses measured by the GST-VP1-based immunoassay and a VP1 VLP-based enzyme-linked immunosorbent assay were highly correlated (Spearman's ρ = 0.823, P < 0.001). The bead-based pan-HPyV multiplex immunoassay is a reliable tool to determine HPyV-specific seroresponses with high reproducibility and specificity and is suitable for use in seroepidemiological studies.
Subject(s)
Antibodies, Viral/blood , Immunoglobulin G/blood , Polyomavirus Infections/diagnosis , Polyomavirus/immunology , Seroepidemiologic Studies , Capsid Proteins/blood , Capsid Proteins/genetics , Capsid Proteins/immunology , Cross Reactions , Fluorescence , Glutathione Transferase/genetics , Humans , Immunoassay/instrumentation , Immunoassay/methods , Immunocompromised Host , Immunologic Tests/instrumentation , Immunologic Tests/methods , Polyomavirus Infections/immunology , Polyomavirus Infections/virology , Reproducibility of Results , Sensitivity and Specificity , Viral Fusion Proteins/genetics , Viral Fusion Proteins/immunologyABSTRACT
BACKGROUND: To investigate the predictive value of chemokine CCL27 for identifying early stage nasopharyngeal carcinoma (NPC) patients within a population seropositive for Epstein-Barr virus (EBV) capsid antigen-specific IgA (VCA-IgA). METHODS: CCL27 in plasma samples from 104 NPC patients, 112 VCA-IgA-positive healthy donors, and 140 VCA-IgA-negative normal subjects was measured by ELISA. Expression of CCL27 in nasopharyngeal tissue from 20 VCA-IgA-positive healthy donors and 20 NPC patients was examined by immunohistochemical staining. RESULTS: Levels of CCL27 in the plasma of VCA-IgA-positive healthy donors (607.33 ± 218.81 pg/ml) were significantly higher than the levels in all NPC patients (437.09 ± 217.74, P = < 0.0001) and in the subset of patients with early stage NPC (463.85 ± 226.17, P = 0.0126). Plasma CCL27 levels were significantly lower in the VCA-IgA-negative normal subjects (358.22 ± 133.15 pg/ml) than in either the VCA-IgA-positive healthy donors (P < 0.0001) or the NPC patients (P = 0.0113). CCL27 protein was detected in 16 of 20 (80%) nasopharyngeal tissue samples from VCA-IgA-positive healthy donors and in 3 of 20 (15%) tumor tissue samples from NPC patients. There was no relationship between CCL27 levels and VCA-IgA titers or plasma EBV DNA content. Receiver operating characteristic (ROC) curves demonstrated that plasma CCL27 levels had a sensitivity of 67.00%, a specificity of 73.10%, and an area under the ROC of 0.725 (95% confidence interval [CI]: 0.657-0.793) for distinguishing between NPC patients and VCA-IgA-positive healthy donors. Further analysis showed that CCL27 levels could distinguish between early stage NPC patients and VCA-IgA-positive healthy donors with an area under the ROC of 0.712 (95% CI: 0.560-0.865), a sensitivity of 59.80%, and a specificity of 84.60%. CONCLUSIONS: Chemokine CCL27 could successfully identify NPC patients within a VCA-IgA-positive population.
Subject(s)
Antibodies, Viral/blood , Biomarkers, Tumor/blood , Capsid Proteins/immunology , Carcinoma/diagnosis , Chemokine CCL27/blood , Epstein-Barr Virus Infections/complications , Immunoglobulin A/blood , Nasopharyngeal Neoplasms/diagnosis , Adult , Aged , Area Under Curve , Capsid Proteins/blood , Carcinoma/blood , Carcinoma/virology , Case-Control Studies , Epstein-Barr Virus Infections/virology , Female , Follow-Up Studies , Herpesvirus 4, Human/isolation & purification , Humans , Male , Middle Aged , Nasopharyngeal Carcinoma , Nasopharyngeal Neoplasms/blood , Nasopharyngeal Neoplasms/virology , Prognosis , Survival RateABSTRACT
BACKGROUND: Worldwide about 1.5 million clinical cases of hepatitis A virus (HAV) infections occur every year and increasingly countries are introducing HAV vaccination into the childhood immunization schedule with a single dose instead of the originally licenced two dose regimen. Diagnosis of acute HAV infection is determined serologically by anti-HAV-IgM detection using ELISA. Additionally anti-HAV-IgG can become positive during the early phase of symptoms, but remains detectable after infection and also after vaccination against HAV. Currently no serological marker allows the differentiation of HAV vaccinated individuals and those with a past infection with HAV. Such differentiation would greatly improve evaluation of vaccination campaigns and risk assessment of HAV outbreaks. Here we tested the HAV non-structural protein 2A, important for the capsid assembly, as a biomarker for the differentiation of the immune status in previously infected and vaccinated individuals. METHODS: HAV antigens were recombinantly expressed as glutathione-S-transferase (GST) fusion proteins. Using glutathione tagged, magnetic fluorescent beads (Luminex®), the proteins were affinity purified and used in a multiplex serological assay. The multiplex HAV assay was validated using 381 reference sera in which the immune status HAV negative, vaccinated or infected was established using the Abbott ARCHITECT® HAVAb-IgM or IgG, the commercial HAV ELISA from Abnova and documentation in vaccination cards. RESULTS: HAV multiplex serology showed a sensitivity of 99% and specificity of 95% to detect anti-HAV IgG/IgM positive individuals. HAV biomarker 2A allowed the differentiation between previously infected and vaccinated individuals. HAV vaccinated individuals and previously infected individuals could be identified with 92% accuracy. CONCLUSION: HAV biomarker 2A can be used to differentiate between previously HAV-vaccinated and naturally infected individuals. Within a multiplex serological approach this assay can provide valuable novel information in the context of outbreak investigations, longitudinal population based studies and evaluations of immunization campaigns.
Subject(s)
Biomarkers/blood , Cysteine Endopeptidases/blood , Hepatitis A virus/immunology , Hepatitis A/blood , Hepatitis A/diagnosis , Viral Proteins/blood , Adolescent , Adult , Capsid Proteins/blood , Capsid Proteins/immunology , Child , Child, Preschool , Cysteine Endopeptidases/immunology , Hepatitis A/immunology , Hepatitis A/virology , Hepatitis A Antibodies/blood , Hepatitis A Antibodies/immunology , Humans , Immunoglobulin G/blood , Immunoglobulin G/immunology , Immunoglobulin M/blood , Immunoglobulin M/immunology , Infant , Infant, Newborn , Vaccination/methods , Viral Proteins/immunologyABSTRACT
Human norovirus is a leading cause of gastroenteritis worldwide. Although two in vitro cultivation methods have been reported, they cannot provide mechanistic insights into viral inactivation. Receptor-binding assays supplement these assays and give insight into capsid integrity. We present a streamlined version of a receptor-binding assay with minimal time-to-result while maintaining accuracy and high throughput. We validate assay performance for physical and chemical inactivation treatments of a norovirus GII.4 capsid. The assay produces a high positive/negative ratio (25.3 ± 4.9) in <2.5 h and has a limit of detection of 0.1 µg/ml capsid. This method is a valuable additional tool for understanding human norovirus inactivation.
Subject(s)
Blood Group Antigens/isolation & purification , Capsid Proteins/blood , Gastroenteritis/virology , Norovirus/isolation & purification , Amino Acid Sequence/genetics , Blood Group Antigens/immunology , Gastroenteritis/diagnosis , Genotype , Humans , Norovirus/genetics , Norovirus/immunology , Norovirus/pathogenicity , Protein BindingABSTRACT
BACKGROUND: Epstein Barr virus (EBV) plays a causal role in some diseases, including infectious mononucleosis, lymphoproliferative diseases and nasopharyngeal carcinoma. Detection of EBV infection has been shown to be a useful tool for diagnosing EBV-related diseases. In the present study, we compared the performance of molecular tests, including fluorescence in situ hybridization (FISH) and EBV real-time PCR, to those of serological assays for the detection of EBV infection. METHODS: Thirty-eight patients with infectious mononucleosis (IM) were enrolled, of whom 31 were diagnosed with a mild type, and seven were diagnosed with IM with haemophagocytic lymphohistiocytosis and chronic active EBV infection. Twenty healthy controls were involved in the study. The atypical lymphocytes in peripheral blood were detected under a microscope and the percentage of positive cells was calculated. EBV DNA load in peripheral blood was detected using real-time PCR. The FISH assay was developed to detect the EBV genome from peripheral blood mononuclear cells (PBMC). Other diagnosis methods including the heterophil agglutination (HA) test and EBV-VCA-IgM test, to detect EBV were also compared. SPSS17.0 was used for statistical analysis. RESULTS: In all, 5-41% atypical lymphocytes were found among the PBMC in mild IM patients, whereas 8-51% atypical lymphocytes were found in IM patients with haemophagocytic lymphohistiocytosis and chronic active EBV infection patients. There was no significant difference in the ratios of atypical lymphoma between patients of the different types. We observed that 71.2% of mild IM patients and 85.7% of IM patients with haemophagocytic lymphohistiocytosis and chronic active EBV infection patients were positive for EBV-VCA-IgM. EBV-VCA-IgM was negative in all healthy control subjects. In addition, 67.1% of mild IM patients tested heterophile antibody positive, whereas 71.4% of IM patients with haemophagocytic lymphohistiocytosis and chronic active EBV infection tested positive. EBV DNA detected using real-time PCR was observed in 89.5% of these IM patients. The EBV genome was detected by the FISH assay in 97.4% of the IM patients. The EB viral loads detected by FISH and real-time PCR increased with the severity of IM. The EBV genome was detected in almost all the PBMC of IM with haemophagocytic lymphohistiocytosis and chronic active EBV infection patients. CONCLUSION: Molecular tests, including FISH and EBV real-time PCR, are more sensitive than serological assays for the detection of EBV infection. The FISH assay detecting EBV copies in unfractionated whole blood is preferable and superior to plasma real-time PCR in its reflection of the absolute viral burden circulating in the patients.
Subject(s)
Herpesvirus 4, Human/genetics , In Situ Hybridization, Fluorescence/methods , Infectious Mononucleosis/virology , Viral Load/methods , Adolescent , Antigens, Viral/blood , Capsid Proteins/blood , Case-Control Studies , Child , Child, Preschool , DNA, Viral/blood , Epstein-Barr Virus Infections/diagnosis , Epstein-Barr Virus Infections/virology , Female , Herpesvirus 4, Human/immunology , Herpesvirus 4, Human/pathogenicity , Humans , Infant , Leukocytes, Mononuclear/virology , Lymphohistiocytosis, Hemophagocytic/virology , Male , Plasma/virology , Real-Time Polymerase Chain Reaction , Sensitivity and SpecificitySubject(s)
Antibodies, Viral/blood , Caliciviridae Infections/blood , Capsid Proteins/blood , Norovirus/isolation & purification , Animals , Antibodies, Viral/immunology , Caliciviridae Infections/immunology , Caliciviridae Infections/virology , Capsid Proteins/immunology , Gastroenteritis/blood , Gastroenteritis/immunology , Gastroenteritis/virology , Genotype , Humans , Norovirus/pathogenicity , RabbitsABSTRACT
BACKGROUND: Epstein-Barr virus (EBV)-associated T/natural killer (NK)-lymphoproliferative disorders (LPDs) include hydroa vacciniforme (HV) and hypersensitivity to mosquito bites (HMB). The pathomechanisms of these diseases are still unclear. OBJECTIVE: To understand the inflammatory process, we examined EBV reactivation markers, BZLF1 and BDRF1 mRNA in the tissue and blood from patients with EBV-associated T/NK-LPDs. METHODS: Sixty-four patients with EBV-associated LPDs and epithelial neoplasms, and EBV+ cell line cells were studied. DNase-treated and resistant EBV DNA load in blood and cell culture supernatants were calculated. An EBV reactivation signal was analyzed in the tissue, blood and cell line cells. RESULTS: In the tissue, BZLF1 mRNA was detected in 5 of 6 (83%) samples of EBV+ epithelial neoplasms, 16 of 21 (76%) of EBV+ lymphomas, and 5 of 15 (33%) of systemic HV and/or HMB, but negative in all 15 patients with classical HV. In the blood, BZLF1 mRNA was detected in only one of 19 (5.3%) samples of EBV-associated T/NK-LPDs. A down-stream reactivation signal, BDRF1 mRNA was expressed in all 6 samples of EBV+ epithelial neoplasms, but it was positive in only one of 15 (6.7%) samples from systemic HV and HMB in the tissue. EBV+ T/NK-cell line cells treated with phorbol 12-myristate 13-acetate produced BZLF1 and BDRF1 mRNA, and encapsidated EBV DNA was detected in the culture supernatants of cell line cells. CONCLUSION: Stimulation-induced EBV reactivation occurred both in vivo and in vitro, but it was almost abortive in vivo. Reactivation-related EBV antigens might be responsible for induction of systemic HV and HMB.
Subject(s)
Culicidae , Herpesvirus 4, Human/physiology , Hydroa Vacciniforme/immunology , Hypersensitivity/etiology , Insect Bites and Stings/immunology , Lymphoproliferative Disorders/immunology , Animals , Antigens, Viral/blood , Antigens, Viral/immunology , Capsid Proteins/blood , Capsid Proteins/immunology , Herpesvirus 4, Human/isolation & purification , Humans , Hydroa Vacciniforme/virology , Insect Bites and Stings/complications , Killer Cells, Natural/immunology , RNA, Messenger/analysis , RNA, Viral/analysis , Trans-Activators/analysisSubject(s)
BK Virus/genetics , Capsid Proteins/genetics , DNA, Viral/genetics , Hematopoietic Stem Cell Transplantation/adverse effects , Opportunistic Infections/virology , Polyomavirus Infections/virology , Tumor Virus Infections/virology , BK Virus/immunology , Biomarkers/blood , Capsid Proteins/blood , Cystitis/blood , Cystitis/virology , DNA, Viral/blood , Hemorrhage/blood , Hemorrhage/virology , Humans , Immunocompromised Host , Immunosuppressive Agents/adverse effects , Opportunistic Infections/blood , Opportunistic Infections/diagnosis , Opportunistic Infections/immunology , Polymerase Chain Reaction , Polyomavirus Infections/blood , Polyomavirus Infections/diagnosis , Polyomavirus Infections/immunology , Predictive Value of Tests , Prospective Studies , Time Factors , Transplantation, Homologous , Tumor Virus Infections/blood , Tumor Virus Infections/diagnosis , Tumor Virus Infections/immunology , Viral LoadABSTRACT
BACKGROUND: Merkel cell polyomavirus (MCPyV) is the main aetiological agent of Merkel cell carcinoma (MCC). Serum antibodies against the major MCPyV capsid protein (VP1) are detected in the general population, whereas antibodies against MCPyV oncoproteins (T antigens) have been reported specifically in patients with MCC. OBJECTIVES: The primary aim was to assess whether detection of serum antibodies against MCPyV proteins at baseline was associated with disease outcome in patients with MCC. The secondary aim was to establish whether evolution of these antibodies during follow-up was associated with the course of the disease. METHODS: Serum T-antigen and VP1 antibodies were assessed by enzyme-linked immunosorbent assay using recombinant proteins in a cohort of 143 patients with MCC, including 84 patients with serum samples available at baseline. RESULTS: Low titres of VP1 antibodies at baseline (< 10 000) were significantly and independently associated with increased risk of recurrence [hazard ratio (HR) 2·71, 95% confidence interval (CI) 1·13-6·53, P = 0·026] and death (HR 3·74, 95% CI 1·53-9·18, P = 0·004), whereas T-antigen antibodies were not found to be associated with outcome. VP1 antibodies did not differ between patients in remission and those with recurrence or progression during follow-up. However, T-antigen antibodies were more frequently detected in patients with recurrence or progression at 12 months (P = 0·020) and 24 months (P = 0·016) after diagnosis. CONCLUSIONS: VP1 antibodies constitute a prognostic marker at baseline, whereas T-antigen antibodies constitute a marker of disease recurrence or progression if detected > 12 months after diagnosis.